Conditions: Multiple Myeloma Non-hodgkin's Lymphoma Hodgkin's Disease
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 12
Healthy volunteers: no

Brief summary:
This Phase II study is to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 alone or in combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease.

Detailed description:

Arms:
arm 1: TG-0054 (3.14 mg/kg)

Interventions: intervention 1: TG-0054
Intervention descriptions: intervention 1: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)

Protocol document: